Advertisement
Research Article

Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy

  • Jeffrey A Johnson mail,

    To whom correspondence should be addressed. E-mail: JJohnson1@cdc.gov

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Jin-Fen Li,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Xierong Wei,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Jonathan Lipscomb,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • David Irlbeck,

    Affiliation: GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • Charles Craig,

    Affiliation: GlaxoSmithKline, Stevenage, United Kingdom

    X
  • Amanda Smith,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Diane E Bennett,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Michael Monsour,

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Paul Sandstrom,

    Affiliation: National HIV and Retrovirology Laboratories, Public Health Agency of Canada, Ottawa, Ontario, Canada

    X
  • E. Randall Lanier,

    Affiliation: GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America

    X
  • Walid Heneine

    Affiliation: Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Published: July 29, 2008
  • DOI: 10.1371/journal.pmed.0050158

Reader Comments (1)

Post a new comment on this article